Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for reducing side effects of leflunomide

A technology for side effects and fomit, which is applied in the field of medicines to reduce the side effects of levomide, can solve the problems of elevated liver enzymes, affecting treatment, and reducing the quality of life of patients

Inactive Publication Date: 2017-09-15
张凤霞
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, immunosuppressive agents are often used in clinical treatment. Although there are certain curative effects, the side effects are obvious.
Leflunomide is a new type of immunosuppressant, and its curative effect has gradually been confirmed, but its toxic and side effects cannot be ignored. Diarrhea and elevated liver enzymes often appear during treatment, which not only affects treatment, but also reduces the quality of life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0009] Embodiment 1: The drug for reducing the side effects of Leformide consists of 10 parts of Leformide, 40 parts of microcrystalline cellulose, 30 parts of starch, 3 parts of polyethylene glycol, 1 part of magnesium stearate, 6 parts of biological preparations, Made from 4 parts of sodium lauryl sulfate and 30 parts of hydroxypropyl cellulose. Pulverize leflunomide and biological preparations, weigh leflunomide, biological preparations, microcrystalline cellulose, starch, sodium lauryl sulfate, and polyethylene glycol and mix well, then add 8% hydroxypropyl Appropriate amount of cellulose aqueous solution, made into soft material, granulated, air-dried, granulated, added with prescribed amount of magnesium stearate, mixed evenly, compressed into tablets, ready to be obtained. Described polyethylene glycol is polyethylene glycol 4000. The biomass powder is mixed and pulverized by 20 parts of Xiangmu Jungui, 80 parts of Huangsuo Meigen, and 15 parts of Centella asiatica, ad...

Embodiment approach 2

[0010] Embodiment 2: The drug for reducing the side effects of Leformide consists of 14 parts of Leformide, 50 parts of microcrystalline cellulose, 40 parts of starch, 6 parts of polyethylene glycol, 3 parts of magnesium stearate, 10 parts of biological preparations, Made from 6 parts of sodium lauryl sulfate and 36 parts of hydroxypropyl cellulose, the preparation method is the same as the first embodiment.

Embodiment approach 3

[0011] Embodiment 3: The drug for reducing the side effects of Leformide consists of 12 parts of Leformide, 45 parts of microcrystalline cellulose, 35 parts of starch, 4 parts of polyethylene glycol, 2 parts of magnesium stearate, 8 parts of biological preparations, It is prepared by 5 parts of sodium lauryl sulfate and 33 parts of hydroxypropyl cellulose, and the preparation method is the same as the first embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for reducing side effects of leflunomide and belongs to the technical field of drugs. The drug for reducing the side effects of the leflunomide is prepared from leflunomide and auxiliary materials of a biologic preparation. A clinical test proves that the problem that the leflunomide easily generates the side effect during clinical treatment of polymyositis can be effectively solved.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a medicine for reducing the side effect of leformide in the clinical treatment of polymyositis. Background technique [0002] Polymyositis is a non-suppurative inflammatory myopathy of striated muscle, which can involve multiple systems and organs. It is a relatively difficult immune disease caused by autoimmune system disorders. Polymyositis is characterized by symmetrical weakness of the proximal extremities, pharynx, and neck muscles, and its etiology remains unclear. It is generally characterized by muscle tenderness and elevated serum enzymes. It is a diffuse muscle inflammatory disease, and most of them believe that it is related to the autoimmune system. At present, immunosuppressive agents are often used clinically. Although there are certain curative effects, the side effects are obvious. Leflunomide is a new type of immunosuppressant, and its curative ef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/73A61K31/42A61K9/20A61P21/00A61P29/00
CPCA61K36/63A61K9/2054A61K9/2059A61K31/42A61K36/23A61K36/73
Inventor 张凤霞
Owner 张凤霞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com